Expanded Access for KHK2455

NCT04321694 | Unknown

• 1 other identifier: Expanded Access for KHK2455
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.

Conditions

Glioblastoma Multiforme

Interventions

KHK2455 DRUG

Also known as: Mogamulizumab

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Sponsors & Collaborators

• Kyowa Kirin, Inc.: lead
• University of New Mexico Cancer Center: collaborator

MeSH Terms

Conditions

Glioblastoma

Interventions

mogamulizumab

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 21, 2020
• First Posted: March 25, 2020
• Last Updated: April 25, 2024

Record last verified: 2024-04